- Home
- VCEL
VCEL
Vericel Corporation
as of 02-13-2026 3:44pm EST
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 2.0B | IPO Year: | 1997 |
| Target Price: | $57.50 | AVG Volume (30 days): | 417.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.25 | EPS Growth: | 236.54 |
| 52 Week Low/High: | $29.24 - $58.77 | Next Earning Date: | 02-26-2026 |
| Revenue: | $258,716,999 | Revenue Growth: | 14.05% |
| Revenue Growth (this year): | 18.02% | Revenue Growth (next year): | 18.52% |
| P/E Ratio: | 145.81 | Index: | N/A |
| Free Cash Flow: | 20.4M | FCF Growth: | N/A |
AI-Powered VCEL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Vericel Corporation (VCEL)
Director
Avg Cost/Share
$34.66
Shares
7,000
Total Value
$242,620.00
Owned After
15,100
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$40.48
Shares
10,000
Total Value
$404,800.00
Owned After
16,080
SEC Form 4
Director
Avg Cost/Share
$37.83
Shares
2,500
Total Value
$94,575.00
Owned After
25,602
SEC Form 4
Director
Avg Cost/Share
$37.97
Shares
2,500
Total Value
$94,925.00
Owned After
25,602
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$39.14
Shares
1,652
Total Value
$64,659.28
Owned After
66,562
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| MCLAUGHLIN KEVIN F | VCEL | Director | Feb 11, 2026 | Sell | $34.66 | 7,000 | $242,620.00 | 15,100 | |
| Halpin Michael | VCEL | Chief Operating Officer | Jan 7, 2026 | Sell | $40.48 | 10,000 | $404,800.00 | 16,080 | |
| Wotton Paul K | VCEL | Director | Dec 3, 2025 | Sell | $37.83 | 2,500 | $94,575.00 | 25,602 | |
| Wotton Paul K | VCEL | Director | Dec 2, 2025 | Sell | $37.97 | 2,500 | $94,925.00 | 25,602 | |
| Hopper Jonathan Mark | VCEL | Chief Medical Officer | Dec 2, 2025 | Sell | $39.14 | 1,652 | $64,659.28 | 66,562 |
Compare VCEL vs Leading Stocks
See how VCEL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "VCEL Vericel Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.